Skip to main content
Publications
Pe M, Alanya A, Falk RS, Amdal CD, Bjordal K, Chang J, Cislo P, Coens C, Dirven L, Speck RM, Fitzgerald K, Galinsky J, Giesinger JM, Holzner B, Le Cessie S, O'Connor D, Oliver K, Pawar V, Quinten C, Schlichting M, Ren J, Roychoudhury S, Taphoorn MJB, Velikova G, Wintner LM, Griebsch I, Bottomley A, SISAQOL-IMI Consortium. Setting international standards in analyzing patient-reported outcomes and quality of life endpoints in cancer clinical trials-innovative medicines nitiative (SISAQOL-IMI): stakeholder views, objectives, and procedures. Lancet Oncol. 2023 Jun;24(6):e270-83. doi: 10.1016/S1470-2045(23)00157-2
Motzer R, Porta C, Alekseev B, Rha SY, Choueiri TK, Mendez-Vidal MJ, Hong SH, Kapoor A, Goh JC, Eto M, Bennett L, Wang J, Pan JJ, Saretsky TL, Perini RF, He CS, Mody K, Cella D. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. Lancet Oncol. 2022 Jun;23(6):768-80. doi: 10.1016/S1470-2045(22)00212-1
Oakes G, Soleas I, Woodward G, Ko D, Eberg M, Tu J, Khan A, Wang X, Gorzkiewicz V, Couris C, Medved W, Leeb K. Comparison of outcomes following coronary artery bypass graft surgery and percutaneous coronary intervention in Ontario as reported by the cardiac care network of Ontario and the Canadian Institute for Health Information. Poster presented at the Canadian Cardiovascular Congress 2017; October 21, 2017. Vancouver, British Columbia. [abstract] Can J Cardiol. 2017 Oct; 33(10 Suppl):S134-5. doi: 10.1016/j.cjca.2017.07.261